Glucagon Resistance in Patients With MASLD and T2DM

Inclusion Criteria: * BMI \> 26 kg/m² * confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) min. 6 months prior enrollment * steatosis FF% \> 5,6% on MR spectroscopy for MAFLD group Exclusion Criteria: * Alcohol abuse (\>10 units per week for both sexes) or other substance abuse * Smoking * Current or previous malignant disease * Blood donation within the last 3 months prior to the study day * Participation in studies involving radioactive isotopes within the past 3 months * Pregnancy * Severely dysregulated type 2 diabetes mellitus (haemoglobin A1c ≥ 100 mmol/mol) * C-peptide \< 200 pmol/L * Previous acute myocardial infarction (AMI) * Clinical symptoms of heart failure * Current or previous malignant disease * Known ongoing systemic disease, except for dyslipidaemia and hypertension * Regular use of medication that may affect lipid and glucose metabolism, including insulin treatment, regular use of over-the-counter medications, and hormonal contraception. Exceptions: 1. Participants treated with statins may be included following a 2-week washout period prior to the experimental study day. 2. Participants receiving oral glucose-lowering therapy for T2DM and antihypertensive medication may be included provided that medication is withheld on the study day only. 3. Participants receiving weekly injectable glucagon-like peptide-1 receptor agonists (GLP-1 analogues) may be included following a 1-week washout period prior to the study day.